Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY)

81 filings reported holding ADAPY - Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share as of Q3 2025.
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) has 54 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 42,101,464 shares of 1,571,428,571 outstanding shares and own 2.7% of the company stock.
Largest 10 shareholders include Long Focus Capital Management, LLC (18,577,821 shares), UBS Group AG (6,667,358 shares), RENAISSANCE TECHNOLOGIES LLC (4,054,089 shares), MORGAN STANLEY (3,666,061 shares), JANE STREET GROUP, LLC (2,805,345 shares), ACADIAN ASSET MANAGEMENT LLC (1,485,153 shares), BANK OF AMERICA CORP /DE/ (1,319,669 shares), Empirical Finance, LLC (800,000 shares), B. Riley Wealth Advisors, Inc. (500,000 shares), and Rathbones Group PLC (432,818 shares).
This table shows the top 54 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.